Original language | English (US) |
---|---|
Pages (from-to) | E5-E8 |
Journal | American Journal of Hematology |
Volume | 96 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2021 |
ASJC Scopus subject areas
- Hematology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. / Cornell, Robert; Hari, Parameswaran; Tang, Shijie; Biran, Noa; Callander, Natalie; Chari, Ajai; Chhabra, Saurabh; Fiala, Mark A.; Gahvari, Zhubin; Gandhi, Ujjawal; Godby, Kelly; Gupta, Ridhi; Jagannath, Sundar; Jagosky, Megan; Kang, Yubin; Kansagra, Ankit; Kauffman, Michael; Kodali, Saranya; Kumar, Shaji K.; Lakshman, Arjun; Liedtke, Michaela; Lonial, Sagar; Ma, Xiwen; Malek, Ehsan; Mansour, Joshua; McGehee, Elizabeth F.; Neppalli, Amarendra; Paul, Barry; Richardson, Paul; Scott, Emma C.; Shacham, Sharon; Shah, Jatin; Siegel, David S.; Umyarova, Elvira; Usmani, Saad Z.; Varnado, William; Vij, Ravi; Costa, Luciano.
In: American Journal of Hematology, Vol. 96, No. 1, 01.2021, p. E5-E8.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH
AU - Cornell, Robert
AU - Hari, Parameswaran
AU - Tang, Shijie
AU - Biran, Noa
AU - Callander, Natalie
AU - Chari, Ajai
AU - Chhabra, Saurabh
AU - Fiala, Mark A.
AU - Gahvari, Zhubin
AU - Gandhi, Ujjawal
AU - Godby, Kelly
AU - Gupta, Ridhi
AU - Jagannath, Sundar
AU - Jagosky, Megan
AU - Kang, Yubin
AU - Kansagra, Ankit
AU - Kauffman, Michael
AU - Kodali, Saranya
AU - Kumar, Shaji K.
AU - Lakshman, Arjun
AU - Liedtke, Michaela
AU - Lonial, Sagar
AU - Ma, Xiwen
AU - Malek, Ehsan
AU - Mansour, Joshua
AU - McGehee, Elizabeth F.
AU - Neppalli, Amarendra
AU - Paul, Barry
AU - Richardson, Paul
AU - Scott, Emma C.
AU - Shacham, Sharon
AU - Shah, Jatin
AU - Siegel, David S.
AU - Umyarova, Elvira
AU - Usmani, Saad Z.
AU - Varnado, William
AU - Vij, Ravi
AU - Costa, Luciano
N1 - Funding Information: We would like to especially thank all the patients who participated in the studies, and their families. The STORM study (NCT02336815) and the present analysis were funded by Karyopharm Therapeutics, Newton, Massachusetts. The MAMMOTH study was not commercially funded. The authors also acknowledge Liz Anfield, Prime Global, Knutsford, UK, for medical writing support, under the direction of the authors, which was funded by Karyopharm Therapeutics in accordance with Good Publications Practice (GPP3) guidelines. Development of this manuscript was supported by Karyopharm Therapeutics. Funding Information: R.C. reports honoraria from Karyopharm Therapeutics, Takeda, Janssen, Sanofi, and GlaxoSmithKline; P.H. reports honoraria from Bristol Myers Squibb, Takeda, Amgen, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Sanofi, and Pharmacyclics; S.T., J.S., M.K., and X.M. report being employed by and owning stock in Karyopharm Therapeutics; N.B. reports honoraria and speakers' bureau participation for Celgene, Amgen, Janssen, and Takeda; consulting or advisory role fees and reimbursement of travel, accommodations, or other expenses from Celgene, Amgen, and Takeda; and research funding from Merck and Amgen; N.C. reports research support from Cellectar; A.C. reports receiving grant support and consulting fees from Millennium/Takeda; grant support, advisory board fees, and consulting fees from Celgene, Novartis Pharmaceuticals, Amgen, and Janssen; consulting fees from Bristol Myers Squibb; advisory board fees from Sanofi and Oncopeptides; grant support from Pharmacyclics; and grant support and advisory board fees from Seattle Genetics; S.C. reports receiving honorarium from Takeda Pharmaceuticals; Funding Information: S.J. reports receiving advisory board fees and consulting fees from Bristol Myers Squibb, Janssen Pharmaceuticals, and Merck; Y.K. reports receiving advisory board fees from Takeda and grant support from InCyte; A.K. reports receiving advisory board fees from Celgene, Janssen, Karyopharm Therapeutics, Takeda, Pfizer and Pharmacyclics; S.K.K. reports receiving advisory board fees from AbbVie, Celgene, Janssen, Takeda Pharmaceuticals, Adaptive Biotechnologies, Kite Pharma, MedImmune/AstraZeneca; receiving research funding from AbbVie, Celgene, Janssen, Merck, Novartis, Roche, Sanofi, Takeda Pharmaceuticals, Kite Pharma and MedImmune/AstraZeneca; and is a member of the Independent Review Committee for Oncopeptides; M.L. reports receiving personal fees from Amgen, Celgene, Pfizer, Takeda, and Janssen; S.L. reports receiving advisory board fees from AbbVie, Amgen, Celgene, Takeda, Janssen Oncology, Juno Therapeutics, Novartis, Merck, Bristol Myers Squibb, and GlaxoSmithKline; and receiving research funding from Bristol Myers Squibb, Celgene, and Takeda; E.M. reports receiving advisory board and speaker fees from Takeda, Sanofi, Amgen and Celgene; speaker fees from Janssen; research funding from Medpacto Inc. and Cumberland; A.N. reports receiving advisory board fees from Amgen; B.P. reports receiving honoraria from Celgene; consulting fees from Amgen and Janssen; P.R. reports receiving grant support and honoraria from Oncopeptides, Celgene, and Takeda; grant support from Bristol Myers Squibb; and honoraria from Amgen, Janssen, and Karyopharm Therapeutics; E.S. reports being employed by GlaxoSmithKline; S.S. reports being employed by and owning stock in Karyopharm Therapeutics, holding patents (8 999 996, 9 079 865, 9 714 226, PCT/US12/048319, and I574957) on hydrazide‐containing nuclear transport modulators and uses, and holding pending patents (PCT/US12/048319, 499/2012, PI20102724, and 012000928) on hydrazide‐containing nuclear transport modulators and uses; D.S. reports receiving honoraria and consulting or advisory role fees for Celgene, Amgen, Merck, Janssen, Bristol Myers Squibb, Takeda, and Karyopharm Therapeutics; speakers' bureau participation for Celgene, Amgen, Merck, Janssen, Bristol Myers Squibb, and Takeda; and research funding from Celgene; S.U. reports receiving consulting fees from Abbvie, Amgen Inc, Bristol Myers Squibb, Celgene, EdoPharma, GlaxoSmithKline, Janssen, Merck, Sanofi, Seattle Genetics, Skyline Dx, Takeda, and TeneoBio; and research funding from Amgen, Array Biopharma, Bristol Myers Squibb, Celgene, Janssen, Merck, Pharmacyclics, Prothena, Sanofi, Seattle Genetics, Skyline Dx, and Takeda; R.V. reports receiving advisory board fees from Bristol Myers Squibb, Takeda, Janssen, Karyopharm Therapeutics, Securabio, and Genentech; and research funding from Bristol Myers Squibb and Takeda; L.C. reports research funding from Amgen and Janssen; and honoraria from Karyopharm Therapeutics, Celgene, Amgen, Janssen, and Sanofi. M.F., Z.G., U.G., K.G., R.G., M.J., S.K., A.L., J.M., E.F.M., E.U., and W.V. declare no conflict of interest.
PY - 2021/1
Y1 - 2021/1
UR - http://www.scopus.com/inward/record.url?scp=85092920395&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092920395&partnerID=8YFLogxK
U2 - 10.1002/ajh.26010
DO - 10.1002/ajh.26010
M3 - Letter
C2 - 32974944
AN - SCOPUS:85092920395
VL - 96
SP - E5-E8
JO - American Journal of Hematology
JF - American Journal of Hematology
SN - 0361-8609
IS - 1
ER -